← All trials
NCT06464510
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Aug 31, 2027
- Completion date
- Sep 30, 2027
- First posted
- Jun 18, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 2800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital do CoracaoLead sponsor
- Brazilian Research In Intensive Care NetworkCollaborator
- Federal University of Sao PauloOfficial
- Hcor Research InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.